Citalopram

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citalopram

Property Description
Active ingredient Citalopram hydrobromide (a racemic mixture)
Form Oral tablet, oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulation of mood and emotional balance
Origin Synthetic (bicyclic phthalane derivative)

Citalopram: Definition and Pharmacological Classification

Citalopram is a synthetic psychotropic medication that belongs to the pharmacological class known as a Selective Serotonin Reuptake Inhibitor (SSRI). This compound, which is a bicyclic phthalane derivative, is primarily designed to affect the brain's natural chemical messenger, serotonin (5-HT). It plays a specific role in modulating neurochemical balance. This selective action helps the system promote emotional stability, making the substance central to treatments where mood regulation is compromised.

Active Ingredient and the Escitalopram Differentiation

The active ingredient is Citalopram, typically supplied as the hydrobromide salt. Citalopram is chemically defined as a racemic mixture, containing equal amounts of two mirror-image molecules called enantiomers: the R-enantiomer and the S-enantiomer. This compositional feature differentiates Citalopram at the INN-level from its successor, Escitalopram, which is the isolated and purified S-enantiomer. The S-enantiomer is the molecule chiefly responsible for the drug's therapeutic effect of serotonin reuptake inhibition. This reliance on the S-enantiomer underscores the substance's highly specific mechanism.

General Therapeutic Purpose and Available Forms

The overall therapeutic purpose of Citalopram is to facilitate a beneficial chemical adjustment in the central nervous system, which helps stabilize mood and maintain emotional balance. It is a single-active-ingredient product designed for oral administration. The medication is commonly supplied as a film-coated oral tablet, though an oral solution is also available. This provision of both solid and liquid forms ensures pharmaceutical flexibility, accommodating patients who may have difficulty swallowing tablets, ensuring ease of consistent daily intake.

Regulatory References

  1. Citalopram LiverTox NIH
  2. MedlinePlus: Escitalopram

What side effects are possible with Citalopram?

Possible side effects and safety information

The official safety profile for Citalopram, as defined by government regulatory documents, outlines adverse reactions categorized by frequency and the body system affected. These classifications are intended to provide a measured expectation of potential effects.

Adverse reactions are grouped into System-Organ Classes, with effects commonly reported in the Nervous System Disorders (e.g., insomnia, somnolence, tremor) and Gastrointestinal Disorders (e.g., dry mouth, nausea, diarrhea).

Reactions are formally classified into frequency bands:

  • Very Common (Affecting ge 1 in 10 patients): Dry mouth, Nausea, Insomnia, Somnolence, Increased sweating.
  • Common (Affecting ge 1 in 100 to < 1 in 10): Decreased appetite, Agitation, Tremor, Dizziness, Constipation, Diarrhea, Sexual dysfunction, and Fatigue.

Regulatory agencies also document Serious Adverse Reactions. Citalopram is associated with a dose-dependent increase in QT-interval prolongation, a serious cardiac risk that can lead to a potentially fatal arrhythmia, Torsade de Pointes. The risk of Serotonin Syndrome is also officially noted, characterized by changes in mental status and neuromuscular activity.

Population-Specific Safety Considerations require a lower maximum daily dose for older adults and individuals with hepatic impairment due to increased drug exposure risks. Furthermore, Citalopram is contraindicated in patients with a known history of QT-interval prolongation or when used concurrently with other medicinal products that prolong the QT interval.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the required actions and documented manifestations following an overdose of Citalopram, which may result in severe, potentially life-threatening outcomes. The profile highlights high-risk events, making immediate emergency response mandatory.

Overdose manifestations, as officially documented, frequently involve the Central Nervous System (CNS) and the Cardiovascular system. Documented signs include somnolence, dizziness, tremor, seizures, nausea, and vomiting. Severe outcomes may progress to coma, cardiac arrest, and Serotonin Syndrome, which is an explicitly documented complication.

Mandatory Emergency Action Triggers

Immediate medical help is required if an overdose is suspected, or if an individual experiences severe symptoms. Individuals must call emergency services (e.g., 911) or a Poison Control Center immediately when the person has collapsed, is unresponsive, or is experiencing trouble breathing.

The official labeling notes that toxicity, particularly the risk of Q-T interval prolongation and subsequent ventricular arrhythmia, is dose-dependent. Furthermore, the risk of severe outcomes and death is increased when the overdose involves co-ingestion of other substances.

Management is strictly symptomatic and supportive, as no specific antidote is known. Procedures include maintaining vital functions and may involve continuous cardiac monitoring and the correction of electrolyte imbalances.

Therapeutic Uses of Citalopram

What Citalopram Treats: Main Uses and Benefits

Citalopram is used across domains where additional symptomatic support is needed in psychiatric care, often applied in clinical settings that involve acute or unstable symptom patterns. The medication is commonly used across conditions presenting with episodic or fluctuating manifestations, primarily Major Depressive Disorder (MDD), and is considered relevant for managing heightened discomfort related to anxiety and compulsive patterns.

The therapeutic benefit of Citalopram may be part of symptomatic management in core affective and anxiety domains, including depressed mood, feelings of worthlessness, the significant loss of interest or pleasure (anhedonia), and recurrent panic attacks or symptoms of Generalized Anxiety. This approach helps address symptom clusters that may become intense or disruptive, especially those that include neurovegetative changes like disturbances to sleep and appetite or difficulty with concentration.

Quick Fact: Relief for Functional Strain

Citalopram may assist with easing the overall burden of symptoms that lead to temporary functional strain, allowing patients to cope more steadily with symptom fluctuations in their daily life.

Regulatory References

  1. Citalopram - StatPearls - NCBI Bookshelf - NIH

Eligibility and Restrictions for Use

Citalopram is formally approved for use only in adults (typically aged 18 years and older) and is not approved for use in pediatric patients.

Contraindicated Populations

Citalopram is strictly contraindicated in patients with a known hypersensitivity to the drug or its ingredients. It must not be used in combination with Monoamine Oxidase Inhibitors (MAOIs), including linezolid or intravenous methylene blue, or within 14 days of stopping an MAOI, due to the risk of Serotonin Syndrome. Concomitant use with Pimozide is also contraindicated due to the risk of QT interval prolongation.

Restricted and High-Risk Populations

  • Age: The maximum recommended dose is reduced to 20 mg/day for patients who are over 60 years of age.
  • Organ Function: The maximum recommended dose is also limited to 20 mg/day for patients with hepatic impairment (reduced liver function).
  • Cardiac Risk: Citalopram is not recommended for use in patients with congenital long QT syndrome or those with a pre-existing long QT interval, uncompensated heart failure, recent acute myocardial infarction, or significant bradycardia, or those taking other drugs that prolong the QT interval, due to the risk of Torsade de Pointes. Electrolyte imbalances such as hypokalemia or hypomagnesemia should be corrected prior to initiation.
  • Metabolism: The maximum dose is limited to 20 mg/day for individuals known to be CYP2C19 poor metabolizers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Citalopram carries significant interaction warnings related to heart rhythm and serotonergic effects.

Interaction Type Interacting Products or Class Restriction / Caution
Serotonin Syndrome Risk Monoamine Oxidase Inhibitors (MAOIs), other serotonergic agents (e.g., SSRIs, SNRIs, Triptans), St. John's wort. Contraindicated with MAOIs (including Linezolid and IV Methylene Blue). A 14-day washout period is required when switching between Citalopram and an MAOI. Use with caution for other serotonergic agents.
Cardiac Risk (QTc Prolongation) Pimozide, other drugs known to prolong the QTc interval (e.g., certain antiarrhythmics, antipsychotics). Contraindicated with Pimozide and other QTc-prolonging agents due to the risk of Torsade de Pointes. Doses are restricted to a maximum of 40 mg/day (general adult) and 20 mg/day (elderly, hepatic impairment, or taking CYP2C19 inhibitors).
Bleeding Risk Anticoagulants (e.g., Warfarin), Antiplatelet drugs (e.g., Aspirin, NSAIDs). Use with caution due to increased risk of bleeding or hemorrhage.
Metabolic Inhibition CYP2C19 Inhibitors (e.g., Cimetidine), CYP3A4 Inhibitors. Citalopram plasma concentration can increase; the maximum dose must be reduced to 20 mg/day when taken with a strong CYP2C19 inhibitor or in patients identified as poor metabolizers.

The drug's interaction profile is heavily influenced by its dose-dependent effect on the QTc interval, leading to strict dosage limitations in specific populations and contraindications with other high-risk cardiac medications. The potential for a rapid, excessive rise in serotonin levels mandates that co-administration with MAOIs is strictly prohibited.

Mechanism of Action

How Citalopram Works: Mechanism of Action

Citalopram operates through the selective inhibition of the Serotonin Transporter (SERT) protein, the primary molecular target. By binding to SERT on the presynaptic neuronal membrane, Citalopram physically prevents the reuptake of the neurotransmitter serotonin (5-HT) from the synaptic cleft back into the neuron. This molecular interaction results in an acute increase in the concentration of serotonin available for binding with postsynaptic receptors.

The sustained elevation of synaptic serotonin initiates downstream neuro-adaptive cascades. Over a period of weeks, this continuous pathway modulation leads to the desensitization and downregulation of specific inhibitory autoreceptors (such as 5 -HT1 A) located on the presynaptic neuron. This crucial receptor adjustment is a neuro-adaptive process that alters the feedback loop regulating serotonin release, resulting in a sustained alteration of central pathway activity and long-term modulation of neurotransmission dynamics.

Dosage and Administration Information

How to use Citalopram: Official Administration Guidelines

This section outlines the typical administration and dosing parameters for Citalopram.

Administration and Timing

Citalopram is taken orally (by mouth) and may be administered as a tablet or oral solution. The medicine should be taken once daily, either in the morning or evening, and preferably at the same time each day. It can be taken with or without food.

If using the oral solution, the bottle must be shaken well before each use, and the dose should be measured using the supplied measuring device. Tablets should be swallowed whole and not chewed.

Official Dosing Schedule

The standard approach involves a starting dose followed by potential adjustment. Maximum daily doses are strictly limited based on age and health status.

Population/Condition Initial Dose (Once Daily) Maximum Recommended Dose (Once Daily)
Adults (Generally < 60 years) 20 mg 40 mg
Geriatric Patients (Age ge 60 years) 20 mg 20 mg
Hepatic Impairment 20 mg 20 mg

Dose increases (from 20 mg to 40 mg) should occur only after at least one week of therapy. For all individuals, doses exceeding the maximum limit are not recommended.

Discontinuation and Missed Doses

Discontinuation must be managed by gradually reducing the dose over time; abrupt cessation is generally avoided in clinical practice. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. Two doses should not be taken at the same time.

Recent Clinical Evidence

Overview of Clinical Research

Citalopram, a selective serotonin reuptake inhibitor (SSRI), is primarily approved for the treatment of Major Depressive Disorder (MDD) in adults. Recent clinical evidence, including meta-analyses of randomized, placebo-controlled trials, focuses on quantifying its effects on symptom severity and response rates.

Studies comparing citalopram to placebo in adults with MDD have consistently indicated a greater patient response rate and reduction in depression symptom scores relative to placebo. However, data concerning remission rates—defined as a return to a nearly symptom-free state—remain inconclusive when compared against placebo in published reports.


Efficacy in Other Conditions

Beyond its core indication, citalopram has been studied for its effects in other anxiety-related conditions:

  • Panic Disorder: Clinical trials have evaluated the use of citalopram in the treatment of panic disorder, with findings suggesting that certain dosage ranges may be associated with a higher likelihood of improvement compared to placebo.
  • Late-Life Anxiety: Early-stage randomized controlled trials have explored the compound's effect in older adults (aged 60 and older) diagnosed with anxiety disorders, primarily Generalized Anxiety Disorder. Initial findings suggested the compound was associated with symptom reduction in this population, but further large-scale replication is needed.

Safety and Tolerability Updates

Recent regulatory advisories and large-scale studies have focused on cardiac risks. Citalopram use is associated with dose-dependent QT interval prolongation, which refers to a change in the electrical activity of the heart. The maximum recommended dose has been revised to reduce the potential risk of an abnormal heart rhythm, particularly for older adults (age 60 and older) or those with existing heart conditions or electrolyte imbalances. Overall, the drug is widely regarded as having a favorable side-effect profile compared to older classes of antidepressants.

Key Studies & References

  1. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: Results from an 8-week randomized, placebo-controlled trial
  2. Citalopram - StatPearls (Citalopram primary FDA-approved clinical use and dosing guidelines)

Frequently Asked Questions (FAQ)

Common questions about Citalopram (FAQ)

Q: What are the signs of serotonin syndrome related to Citalopram?

Serotonin syndrome is a serious, potentially life-threatening reaction that is noted in the official product information. Signs can include mental status changes, such as confusion or agitation, and problems with muscle control, such as tremors or rigid muscles. Regulatory documents describe signs that may also include changes in the nervous system, such as fast heart rate, fluctuations in blood pressure, fever, or excessive sweating.

Q: What are the potential withdrawal symptoms from Citalopram?

Official prescribing information emphasizes that the medication should not be stopped abruptly to minimize the potential for discontinuation symptoms. Symptoms that have been reported upon stopping treatment include mood changes, increased irritability, and anxiety. Patients may also experience dizziness, headache, insomnia, or unusual sensations such as electric shock-like feelings (paresthesia).

Q: What are the most common side effects people report when taking Citalopram?

According to data from clinical trials reported in the official FDA label, the most common side effects that occur in a high percentage of patients are nausea, somnolence (drowsiness), and insomnia (difficulty sleeping). Dry mouth and ejaculatory delay or failure in males are also frequently reported.

Q: Is it difficult to stop taking Citalopram after a long time?

Official instructions state that the dose must always be gradually reduced, or 'tapered,' over a period of time, rather than stopped all at once. The requirement for a managed reduction is intended to minimize the risk of discontinuation symptoms, which indicates that stopping the medication, especially after long-term use, should be done under professional guidance.

Q: How quickly should I expect to feel better after starting Citalopram?

Clinical studies for its approved use in Major Depressive Disorder (MDD) typically show a measurable effect after several weeks. Official product information indicates that it may take between one and four weeks for some patients to begin to notice changes in their symptoms, although individual response times can vary.

Q: Is it true that Citalopram can cause weight gain?

Official adverse reaction reports indicate that weight changes (both gain and loss) are reported as an infrequent reaction in some patients. Some clinical trial data also suggest that weight gain may occur and may be associated with increased appetite in some individuals.

Q: Can Citalopram make you feel more anxious at first?

Official trial data lists anxiety as an infrequent adverse reaction and agitation as a common adverse reaction. Official safety information requires monitoring for worsening anxiety or agitation, particularly during the initial period of treatment, because these effects have been reported.

Q: Is Citalopram primarily used for depression or anxiety?

According to its official FDA labeling, Citalopram is formally approved only for the treatment of Major Depressive Disorder (MDD) in adults. While it is studied for other conditions, MDD is the sole approved indication for its use.

Q: Does Citalopram affect sleep (e.g., cause insomnia or vivid dreams)?

Yes, Citalopram can affect sleep. Official regulatory documents list both insomnia (difficulty falling or staying asleep) and somnolence (drowsiness) as very common or common side effects. Abnormal or vivid dreams are also reported as an infrequent adverse reaction.

Q: Are there any over-the-counter medicines I should definitely avoid while on Citalopram?

Official warnings advise patients to avoid certain over-the-counter medications that can increase the risk of bleeding. These include non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, and aspirin. Individuals should discuss the use of any new over-the-counter medicine with a healthcare professional to confirm suitability.

Q: Can Citalopram interact with alcohol?

The official patient counseling information provided by the FDA indicates that patients should avoid the consumption of alcohol while taking Citalopram.

Q: Are there potential sexual side effects when taking Citalopram?

Yes, Citalopram has been associated with sexual dysfunction, a recognized side effect in official reports. This may include decreased libido and delayed or absent orgasm in females, and ejaculatory delay or failure and erectile dysfunction in males.

Q: Can Citalopram cause stomach issues like nausea or diarrhea?

Yes, gastrointestinal issues are among the most frequently reported side effects. Nausea is listed as a very common side effect, and diarrhea is also listed as a common side effect in the official safety profile.

Q: Why do some people feel dizzy or lightheaded on Citalopram?

Dizziness is listed as a common adverse reaction in official safety data. The medication has also been associated with postural hypotension (a drop in blood pressure upon standing up), which can cause the feeling of being lightheaded.

Q: What kind of dietary restrictions are necessary with Citalopram?

Citalopram is unique in that it can be taken with or without food, and the regulatory label does not mandate any specific dietary restrictions. This contrasts with older antidepressant classes which sometimes had strict food rules.

Q: Does Citalopram affect driving or operating machinery?

Official safety sections warn that Citalopram can cause drowsiness and dizziness, which are central nervous system (CNS) effects. Because these effects may impair a person's judgment, thinking, and motor skills, the official label advises patients to use caution when operating hazardous machinery, including automobiles.

Q: Is Citalopram known to cause memory problems or brain fog?

Official adverse reaction reports have infrequently included central nervous system effects such as amnesia and confusion. These reported effects suggest a potential for some level of cognitive change or 'brain fog' in some patients.

Q: Can Citalopram affect blood pressure?

Yes, changes in blood pressure have been reported in official adverse reaction data. Hypotension (low blood pressure) and postural hypotension are listed as frequent adverse reactions, while hypertension (high blood pressure) is reported infrequently.

Q: What is the purpose of the half-life of Citalopram?

Citalopram has a long average half-life of approximately 35 hours. This measurement is the primary basis for the medication's required once-daily dosing schedule, and it dictates the time needed for the body to clear the drug, which is relevant for switching to other medications.

Q: Does Citalopram affect blood sugar levels?

Official adverse reaction data includes both high blood sugar (hyperglycemia) and low blood sugar (hypoglycemia) as infrequent adverse reactions. This suggests the medication may have an indirect effect on blood glucose regulation.

Q: Can Citalopram cause sweating or hot flashes?

Yes, increased sweating (diaphoresis) is listed as a very common side effect, affecting more than 1 in 10 patients in clinical trials. Hot flashes are also reported in official documentation as an infrequent adverse reaction.

Q: Is it normal to feel tired or lethargic when first starting Citalopram?

Yes, official safety data lists both somnolence (drowsiness) and fatigue as common side effects. These effects are often most noticeable during the initial period after a patient starts taking the medication.

Q: Can Citalopram cause eye problems like blurred vision?

Official safety information lists blurred vision as an infrequent adverse reaction. Furthermore, Citalopram carries a warning about the potential to cause or worsen angle-closure glaucoma, which can lead to vision changes and eye pain in susceptible individuals.

Q: Is it necessary to take Citalopram at the same time every day?

Yes, official prescribing instructions state that the medication should be taken once daily and, preferably, at the same time each day. This is important for maintaining consistent drug levels in the body.

Q: Is Citalopram generally considered addictive?

No, Citalopram is not classified as a controlled substance and is not considered to have an abuse potential by the FDA or the DEA. However, as it can cause discontinuation symptoms if stopped suddenly, a regulated reduction schedule is required by prescribing information.

Q: Why is Citalopram sometimes referred to by the brand name Celexa?

The drug Citalopram is the generic name for the active ingredient. It was originally marketed and is sometimes still referred to to by its registered trade name, Celexa.

Q: Are there specific lab tests required when taking Citalopram?

The FDA recommends monitoring for hyponatremia (abnormally low sodium levels) in certain patients, especially those who are taking diuretics or who are otherwise volume-depleted. This monitoring may require a serum sodium blood test.

Q: Can Citalopram cause a decrease in appetite?

Yes, decreased appetite is listed as a common side effect in the official regulatory documents.

Q: Is Citalopram suitable for teenagers or children?

Official FDA labeling includes a section on pediatric use, which explicitly states that Citalopram is not approved for use in pediatric patients, including children and adolescents.

Q: Can I take Citalopram if I'm breastfeeding?

Official product information states that Citalopram is known to be excreted into human breast milk. The decision to use the medication while breastfeeding requires a risk-benefit assessment by a qualified healthcare professional.

Q: Is Citalopram safe for people with epilepsy or a history of seizures?

Citalopram has not been systematically evaluated in patients who have a seizure disorder. Therefore, official safety guidance specifies that the medication should be used with caution in any patient with a history of seizures.

How should Citalopram be stored and disposed of?

Storage and Disposal of Citalopram

Citalopram must be stored under specific regulatory conditions to maintain stability and ensure safety.

Official Storage Requirements

Condition Requirement
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Protection Keep away from excess heat, moisture, and do not freeze.
Container Must remain in the tightly closed, original container.
Child Safety Store out of the reach and sight of children.

Official Disposal Instructions

For disposal of unused or expired citalopram, official federal guidance recommends using a drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an unappealing substance (like dirt or coffee grounds) and placed in a sealed bag before being discarded in the household trash. The product should not be flushed down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citalopram found in:

A-Z Index: